ห้องสมุดงานวิจัย สำนักงานคณะกรรมการวิจัยแห่งชาติ

THE EFFECT OF <u>Bacopa monnisri</u> EXTRACT ON TAU PROTEIN IN NEURONAL CELLS

KANCHANAT TERNCHCOCHEEP

A Thesis Submitted to the Graduate School of Naresuan University
in Partial Fulfillment of the Requirements
for the Doctor of Philosophy Degree
in Biochemistry
May 2012
Copyright 2012 by Naresuan University

b00254851



THE EFFECT OF <u>Bacopa monnieri</u> EXTRACT ON TAU PROTEIN IN NEURONAL CELLS



KANCHANAT TERNCHOOCHEEP

A Thesis Submitted to the Graduate School of Naresuan University
in Partial Fulfillment of the Requirements
for the Doctor of Philosophy Degree
in Biochemistry
May 2012
Copyright 2012 by Naresuan University

This thesis entitled "The effect of *Bacopa monnieri* extract on Tau protein in neuronal cells" submitted by Kanchanat Ternchoocheep in partial fulfillment of the requirement for the Doctor of Philosophy Degree in Biochemistry is hereby approved.

S. Ky
(Sarawut Kumphune, Ph.D)
SUI WWW. Committee
(Associate Professor Sukkid Yasothornsrikul, Ph.D)
k. Inghaninan Committee
(Associate Professor Kornkanok Ingkaninan, Ph.D)
Committee Committee
(Associate Professor Sutisa Thanoi, Ph.D)
Nuanchabu hutprasit Committee
(Associate Professor Nuanchawee Wetprasit, Ph.D.)
Sittiruk Roytrakul Committee
(Sittiruk Roytrakul, Ph.D)
Approved
K. Perpatwillel

(Assistant Professor Kanungnit Pupatwibul, Ph.D)

Dean of the Graduate School

11 May 2012

ACKNOWLEDGEMENT

I would like to express my deepest appreciation to Venerable Pradhammashinghaburajan (Luangpor Jarun Thitadhammo) for his instruction I followed during working on my dissertation and to my parents for their loves, supports, understanding, and encouraging throughout my study.

I am greatly indebted to "The Commission of Higher Education of Thailand (CHE)" for subsidizing me the fellowship for the shortage program in 2006 and for the exchange program in 2007.

I would like to deeply express my gratitude to Associate Professor Dr. Sukkid Yasothornsrikul, my supervisor, for sacrifying his times and valuable advices on this study, Associate Professor Dr. Kornkanok Ingkaninan, for her generously providing for Bacopa monneiri crude extract and all of its beneficial information, Associate Professor Dr. Suthisa Thanoi for her kindness to offer me an opportunity to learn how immunocytochemistry technique is done and Assistant Professor Dr. Nanteetip Limpeanchob for her kindliness gift the SH-SY5Y cells for all of my study.

Unforgetably, I am very grateful to all staffs in Department of Biochemistry, Faculty of Medical Science, Naresaun University, especially Associate Professor Dr. Dawan Shimbhu for her valuable suggestion and encouraging, Assistant Professor Dr. Jiraporn Tocharus, Dr. Damratsamon Surangkul and Dr. Jongrak Attarat for their friendly technical guides during my research work.

I am also sincerely thank to all members in Associate Professor Dr. Sukkid's laboratory, especially Miss Kanoktip Petcharat, for their warmly collaboration.

The last but not least, I express my especially gratitude to "The Graduated School Naresaun University" for assisting in my dissertation preparation.

Kanchanat Ternchoocheep

Title THE EFFECT OF Bacopa monnieri EXTRACT ON

TAU PROTEIN IN NEURONAL CELLS

Author Kanchnat Ternchoocheep

Advisor Associate Professor Sukkid Yasothornsrikul, Ph.D.

Co-advisor Associate Professor Kornkanok Ingkaninan, Ph.D.

Associate Professor Suthisa Thanoi, Ph.D.

Academic Paper Thesis Ph.D. in Biochemistry, Naresaun University, 2011

Keywords Alzheimer's disease, Bacopa monnieri, Tau protein,

Phosphorylated tau protein, NGF-deprived PC12 cells,

SH-SY5Y cells, Apoptosis, Neurodegenerative disorders

ABSTRACT

E 47335

Bacopa monnieri is a revered ancient Indian Ayurvedic herb specific for cognition enhancing benefit. This research is aimed to measure the effect of the alcoholic BM extract on the viabilities and the amount of Tau protein expression of NGF-deprived PC12 cells or human SH-SY5Y neuroblstoma cells brought up in apoptotic-induced media. The PC12 cells were cultured in normal-serum medium for a week before transferred to low-serum medium for the same period. After that the cultures were raised in normal-serum (NR) or serum-free (SF) medium and each treated with either 0 (control), 50, 100, 150, 200, 250, and 300 µg/ mL BM extract for up to 7 days for MTT viability assay or 0, 50, and 100 μg/ mL BM extract for 2 days for immunoblot assay. The SH-SY5Y cells were brought up in normal-serum medium for a week before differentiation in low-serum medium containing 20 μM Retinoic acid further for a week. Then, the cultures were raised in low-serum medium and treated with absolute 0.025% DMSO, absolute 5µM camptothecin, and either BM extract at final concentration 50-25 µg/ mL for up to 12, 24, and 48 hours for MTT viability assay or 0, 50, and 100 µg/ mL BM extract for 12, 24, and 48 hours for immunoblot assay and Tau gene expression determination. The MTT viabilities were measured and the average cellular viability percentages of each treatment were compared to their corresponding controls daily. Immunoblot assay of the proteins were performed by using total tau (Tau 5), dephosphorylated tau (Tau 1), and glyceraldehydes dehydrogenase (GAPDH) antibodies and then quantified by Scion Image software. Tau 1 immunoreactivity was normalized by total tau. All data in the present study were analyzed by one-way ANOVA with $\alpha = 0.05$. RT-PCR of Tau and GAPDH gene from each condition was performed. The findings of this study revealed that (1) BM extract could improve the cellular viability of the normal neuronal cells and apoptotic-induced neuronal cells, (2) BM extract could be able to abate down both the amount of total Tau (Tau 5) and phosphorylated Tau (at Tau-1 site) expression in apoptotic-induced neuronal cells, and (3) BM extract at both 50 and 100 μ g/ mL concentration could be able to reduce the 3R tau mRNA to express in differentiated SH-SY5Y cells, apoptotic-induced by camptothecin. These results offer a supportive document advocating to the benevolent property of BM extract to be an alternative therapy for neurodegenerative diseases such as Alzheimer's disease.

LIST OF CONTENT

Chapter		Page
I	INTRODUCTION	1
	Rational of the study	1
	Purpose of the study	2
	The research hypothesis.	2
	Significance of the study	3
	Scope of study	3
II	LITERATURE REVIEW	4
	Degenerative Disease, and Alzheimer's disease	4
	Pathology of Alzheimer's disease	7
	Pathogenesis of Alzheimer's disease	8
	Tau protein.	12
	Etiopathogenesis.	14
	Tau protein and dementia	17
	Tau protein and apoptosis	18
	Bacopa monnieri (L.) Wettst	19
Ш	RESEARCH METHODOLOGY	26
	Preparation of BM extract tudy	26
	Cell culture	27
	Cell treatment with BM extract	28
	MTT assay	29
	Antibodies	30
	Immunoblotting	30
	Reverse-transcription PCR	31

LIST OF CONTENT (CONT.)

Chapter	Page
Methodology Diagrams	
Instrument and Material	37
IV RESULTS	40
MTT cell viability	40
Immunoblotting	42
Determination of gene expression.	45
V DISCUSSION	64
VI CONCLUSION	73
REFERENCES	74
APPENDIX	92
RIOCRAPHY	00

LIST OF TABLES

Table	e	Page
1	Relative frequency of dementing disease	5
2	Genetic defect of Alzheimer's	10
3	Clinical study of BM extract in human	24
4	MTT viability percentage of NGF-deprived PC12 cells, treated by BM	
	extract for 7 days in normal-serum RPMI1640 (NR) medium	47
5	MTT viability percentage of NGF-deprived PC12 cells, treated by	
	Bacopa monnieri for 7 days in apoptotic-induced serum-free	
	RPMI1640 medium	49
6	The MTT viability percentage of differentiated SH-SY5Y cells, grown	
	up in only low-serum RPMI 1640 medium for 12 to 72 hours	51

LIST OF FIGURES

gure		Page
1	Prevalence of dementia divided by age in Thailand	6
2	Prevalence expectation of dementia in Thailand during 2005 – 2050	6
3	Diagram of proteolysis of amyloid precursor protein (APP)	9
4	Tau gene and Tau protein structure	13
5	Dynamic equilibrium of tau protein and microtubule association	14
6	The progression of tau protein aggregation	17
7	Structure of some components in Bacopa monniera	21
8	The reduction of MTT to formazan	30
9	MTT viability percentage of NGF-deprived PC12 cells, treated by BM	
	extract for 4 days in normal-serum RPMI1640 (NR) medium	48
10	MTT viability percentage of NGF-deprived PC12 cells, treated by	
	Bacopa monnieri for 2-3 days in apoptotic- induced serum-free	
	RPMI1640 medium	50
11	The MTT viability percentage of the cells, treated by only 0.025%	
	DMSO (vehicle), 5 μ M camptothecin, and BM extract at the 50	
	to 250 μg/ mL concentrations for 12 to 48 hours	52
12	The relative amount of total tau (Tau 5) and dephosphorylated Tau	
	(Tau-1) expression of NGF-deprived PC12 cells in normal-serum	
	RPMI1640, treated with BM extract for 2 days.	53
13	The relative amount of total tau (Tau 5) and dephosphorylated Tau	
	(Tau-1) expression of NGF-deprived PC12 cells in serum-free	
	RPMI1640, treated with BM extract for 2 days	54
14	Tau-1 immunoreactivity of total Tau expression of NGF-deprived	
	PC12 cells treated with BM extract in RPMI1640	
	medium for 48 hours	55

LIST OF FIGURES (CONT.)

Figur	ligure	
15	The relative amount of total Tau (Tau 5) and	
	dephosphorylated Tau (Tau-1) expression of differentiated SH-	
	SY5Y cells at 12 hours	56
16	Tau-1 immunoreactivity normalized to the relative amount of total	
	Tau expression of differentiated SH-SY5Y cells	57
17	The relative amount of total Tau (Tau 5) and dephosphorylated	
	Tau (Tau-1) expression of differentiated SH-SY5Y	
	cells at 24 hours	58
18	Tau-1 immunoreactivity normalized to the relative amount of total	
	Tau expression of differentiated SH-SY5Y cells at 24 hours	59
19	The relative amount of total Tau (Tau 5) and dephosphorylated	
	Tau (Tau-1) expression of differentiated SH-SY5Y cells at	
	48 hours	60
20	Tau-1 immunoreactivity normalized to the relative amount of total	
	Tau expression of differentiated SH-SY5Y cells at 48 hours	61
21	Single-selected immunoblottogram of differentiated SH-SY5Y cells at	
	12 hours	62
22	Tau PCR band products (upper panels of A and B) and GAPDH PCR	
	band products (lower panels of A and B) of differentiated SH-	
	SY5Y cells at 12 and 24 hours (A) and 48 and 72 hours (B)	63
23	Tau mRNA alternative splicing and Tau protein products	72